leadf
logo-loader
viewOncoSil Medical Ltd

OncoSil Medical reveals positive data from pancreatic cancer clinical study

100% disease control rate achieved by the company's device at week 8.

pancreatic cancer
Device delivery via endoscopic ultrasound

OncoSil Medical Ltd’s (ASX:OSL) pancreatic cancer clinical study has demonstrated significant local disease control with up to 73% reduction in tumour volume observed 4 weeks post implant.

The company’s lead product, OncoSil™, is a targeted radioactive isotope, implanted directly into a patient’s pancreatic tumour via an endoscopic ultrasound.

Treatment with OncoSil is intended to deliver more concentrated and localised beta radiation compared to external beam radiation.

OncoSil has provided an overview of early study results at the European Association of Nuclear Medicine (EANM) Congress, which took place in Vienna on 21 October 2017.

Positive data from the first group of patients who completed CT imaging in the 8, 16 and 24-week study follow-up periods was presented by OncoSil.

This early study data is consistent with previously completed studies that validated the safety, efficacy and delivery of the OncoSil™ device.

OncoSil continues to progress patient recruitment of its global pancreatic cancer clinical study program, with 28 subjects now enrolled into the study group.

The company will continue to recruit subjects beyond the initial 20 subject target to gather additional valuable clinical experience and to account for subject loss due to factors such as withdrawal.

It is worth noting that the prognosis for patients diagnosed with pancreatic cancer, regardless of stage, is generally poor; the relative five-year survival rate for all stages combined is circa 5%.

The estimated worldwide market opportunity for OncoSil in pancreatic cancer exceeds $1 billion.

Quick facts: OncoSil Medical Ltd

Price: 0.11 AUD

ASX:OSL
Market: ASX
Market Cap: $88.81 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

White Rock Minerals says deal with Thomson Resources for Mt Carrington is a...

White Rock Minerals Ltd's (ASX:WRM) (OTCQX:WRMCF) Matt Gill speaks to Proactive's Andrew Scott soon after entering into a binding and exclusive term sheet with Thomson Resources Ltd (ASX:TMZ) for a three-stage earn-in and option to a joint venture agreement to progress the Mt Carrington gold and...

9 hours, 14 minutes ago

2 min read